(10E,12Z)-Octadeca-10,12-dienoic acid  (Synonyms: trans-10,cis-12 CLA2)

(10E,12Z)-Octadeca-10,12-dienoic acid (trans-10,cis-12 CLA2) is an orally active PPARα activator and inhibits adipocyte differentiation. (10E,12Z)-Octadeca-10,12-dienoic acid and its downstream metabolites have various antioxidant and antitumor activities. (10E,12Z)-Octadeca-10,12-dienoic acid can induce proinflammatory cytokines and chemokines, which would lead to decreased adipogenesis and insulin resistance in adipose tissue. (10E,12Z)-Octadeca-10,12-dienoic acid can affect many aspects of milk fat synthesis. (10E,12Z)-Octadeca-10,12-dienoic acid reduces expression of lipogenic enzymes and inhibits the desaturation of fatty acids. (10E,12Z)-Octadeca-10,12-dienoic acid can reduce lipoprotein lipase (LPL) activity in cultured 3T3-L1 adipocytes and enhance triacylglycerol release from these cells. (10E,12Z)-Octadeca-10,12-dienoic acid decreases the expression of hepatic stearoyl-CoA desatyrase mRNA in mice. (10E,12Z)-Octadeca-10,12-dienoic acid is associated with changes in mucosal NF-κB and Cyclin D1 protein levels in mice^{[1][2][3][4][5][6]}.

(10E,12Z)-Octadeca-10,12-dienoic acid (Compound trans-10, cis-12) (43.6 μM, 48 h) significantly reduces LPL activity, intracellular triacylglycerol and glycerol whist the glycerol release is significantly enhanced in 3T3-L1 adipocytes^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(10E,12Z)-Octadeca-10,12-dienoic acid (Compound trans-10, cis-12) decreases body fat and increases lean body mass in different animal models^[4].
(10E,12Z)-Octadeca-10,12-dienoic acid (10 g/d, i.v. infusion, 5 d) leads to a linear decrease in milk fat synthesis until reaching a steady state after 3 days in dairy cows^[4].
(10E,12Z)-Octadeca-10,12-dienoic acid (1 g/100 g, added to diet, 8 w) significantly reduces the NF-κB levels in the nuclear fraction of the mucosa and significantly elevates the cyclin D1 levels in C57BL/6J Min mice^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

280.45

C₁₈H₃₂O₂

2420-56-6

Liquid

Colorless to light yellow

CCCCC/C=C\C=C\CCCCCCCCC(O)=O

Room temperature in continental US; may vary elsewhere.

Solution, -20°C, 2 years

• [1]. Houseknecht KL, et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun. 1998 Mar 27;244(3):678-82.  [Content Brief]

  [2]. Shultz TD, et al.Inhibitory effect of conjugated dienoic derivatives of linoleic acid and beta-carotene on the in vitro growth of human cancer cells. Cancer Lett. 1992 Apr 15;63(2):125-33.   [Content Brief]

  [3]. Park Y, et al Conjugated fatty acids as a prevention tool for obesity and osteoporosis[M]//Emerging trends in dietary components for preventing and combating disease. American Chemical Society, 2012: 393-405

  [4]. Gervais, R., et al., (2009). Effects of intravenous infusion of trans-10, cis-12 18:2 on mammary lipid metabolism in lactating dairy cows. Journal of dairy science, 92(10), 5167–5177.  [Content Brief]

  [5]. Park, Y., et al., (1999). Evidence that the trans-10,cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids, 34(3), 235–241.  [Content Brief]

  [6]. Rajakangas, J., et al., (2003). Adenoma growth stimulation by the trans-10, cis-12 isomer of conjugated linoleic acid (CLA) is associated with changes in mucosal NF-kappaB and cyclin D1 protein levels in the Min mouse. The Journal of nutrition, 133(6), 1943–1948.  [Content Brief]